Back HCV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress

The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.

alt

Read more:

EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss

People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.

alt

Read more:

EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer

The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk

Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?

HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

Read more: